Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives: A 60-Year Follow-up Study

JAMA

Volumn 291, Issue 17, 2004, Pages 2086-2091

  Aronson, Naomi E ^a,b,f   Santosham, Mathuram ^c   Comstock, George W ^c   Howard, Robin S ^b   Moulton, Lawrence H ^c   Rhoades, Everett R ^d   Harrison, Lee H ^e  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; PLACEBO;

ADULT; AMERICAN INDIAN; BACTERIAL STRAIN; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; UNITED STATES; ARTICLE; CONTROLLED CLINICAL TRIAL; ESKIMO; ETHNOLOGY; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VACCINATION;

BCG VACCINE; CONTROLLED CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIANS, NORTH AMERICAN; INUITS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUBERCULOSIS; VACCINATION;

EID: 2342584774     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.17.2086     Document Type: Review

References (41)

1. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. JAMA. 1994;271:698-702.
2. Sterne JAC, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis. 1998;2:200-207.
3. Townsend JG, Aronson JD, Saylor R, Parr I. Tuberculosis control among North American Indians. Am Rev Tuberc. 1942;45:41-52.
4. Aronson JD, Aronson CF, Taylor HC. A twenty year appraisal of BCG vaccination in the control of tuberculosis. Arch Intern Med. 1958;101:881-893.
5. Stein SC, Aronson JD. The occurrence of pulmonary lesions in BCG-vaccinated and unvaccinated persons. Am Rev Tuberc. 1953;68:695-712.
6. Aronson JD, Parr EI, Saylor RM. BCG vaccine: its preparation and the local reaction to its injection. Am Rev Tuberc. 1940;42:651-666.
7. Aronson JD, Palmer CE. Experience with BCG vaccine in the control of tuberculosis among North American Indians. Public Health Rep. 1946;61:802-820.
8. Aronson JD. BCG vaccination among American Indians. Am Rev Tuberc. 1948;57:96-99.
9. Aronson JD. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc. 1948;58:255-281.
10. Aronson JD, Aronson CF. Appraisal of protective value of BCG vaccine. JAMA 1952;149:334-343.
11. Statxact5 [computer program]. Cambridge, Mass: Cytel; 2001.
12. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22:1154-1158.
13. Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle. 1979;60:225-231.
14. Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials. 1994;15:247-276.
15. Fine PE. BCG vaccines and vaccination. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York, NY: Marcel Dekker; 2001:503-522.
16. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ. 1977;2:293-295.
17. Comstock GW, Livesay VT, Woolpert SF. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health. 1974;64:283-291.
18. Frimodt-Moller J, Thomas J, Parthasarathy R. Observations on the protective effect of BCG vaccination in a South Indian rural population. Bull World Health Organ. 1964;30:545-574.
19. Rosenthal SR, Loewinsohn E, Graham ML, Liveright D, Thorne MG, Johnson V. BCG vaccination in tuberculous households. Am Rev Respir Dis. 1961;84:690-704.
20. Baily GV, Narain R, Mayurnath S, Vallishayee SR, Guld J. Tuberculosis prevention trial, Madras. Indian J Med Res. 1980;72(suppl):1-74.
21. Datta M, Vallishayee RS, Diwakara AM. Fifteen year follow-up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res. 1999;110:56-69.
22. Ferguson RG, Simes AB. BCG vaccination in Indian infants of Saskatchewan. Tubercle. 1949;30:5-11.
23. Rosenthal SR, Loewinsohn E, Graham ML. BCG vaccination against tuberculosis in Chicago: a twenty year study statistically analyzed. Pediatrics. 1961;28:622-641.
24. Comstock GW, Webster RG. Tuberculosis studies in Muscogee County, Georgia: a 20 year evaluation of BCG vaccination in a school population. Am Rev Respir Dis. 1969;100:839-845.
25. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia: twenty year evaluation of a community trial of BCG vaccination. Public Health Rep. 1976;91:276-280.
26. Frimodt-Moller J, Acharyulu GS, Pillai KK. Observations on the protective effect of BCG vaccination in a South Indian rural population: fourth report. Bull Int Union Tuberc. 1973;48:40-50.
27. Tuberculosis Research Center (ICMR) Chennai. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res. 1999;110:56-69.
28. Medical Research Council. BCG and the role of tuberculosis vaccines in the prevention of tuberculosis in adolescence and early adult life: fourth report. Bull World Health Organ. 1972;46:371-385.
29. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics. 1995;96:29-35.
30. Behr MA. BCG-different strains, different vaccines? Lancet Infect Dis. 2002;2:86-92.
31. Behr MA, Wilson MA, Gill WP, et al. Comparative genomes of BCG vaccines by whole-genome DNA microarray. Science. 1999;284:1520-1523.
32. Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine. 1999;17:915-922.
33. Mori M, Leonardson G, Welty TK. The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. Arch Intem Med. 1992;152:547-550.
34. Baik SH, Park ID, Choi KM, et al. BCG prevents insulinitis in low dose streptozotocin-induced diabetic mice. Diabetes Res Clin Pract. 1999;46:91-97.
35. Lakey JR, Singh B, Wamock GL, Rajotte RV. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation. 1994;57:1213-1217.
36. Dahlquist G, Gothefors L. The cumulative incidence of childhood diabetes in Sweden is unaffected by BCG vaccination. Diabetologia. 1995;38:873-874.
37. Shehadeh N, Calcinaro F, Bradley BJ, Bruchlim I, Vardi P, Lafferty KJ. Effect of adjuvant therapy on the development of diabetes in mouse and man. Lancet 1994;343:706-707.
38. Classen JB, Classen DC. Immunization in the first month of life may explain decline in incidence of IDDM in the Netherlands. Autoimmunity. 1999;31:43-45.
39. Parent ME, Siemiatycki J, Menzies R, Fritschi L, Colle E. BCG vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care. 1997;20:767-772.
40. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant to prevent genital herpes. N Engl J Med. 2002;347:1652-1661.
41. Meinert CL. Data dredging as an analysis technique. In: Clinical Trials: Design, Conduct Analysis. New York, NY: Oxford University Press; 1986:214-215.